VM-26 in colorectal carcinoma: A Southwest Oncology Group study |
| |
| Authors: | Noboru Oishi Thomas R. Fleming Leslie Laufman James S. Ungerleider Ronald B. Natale Albert B. Einstein Jr. Daniel D. Von Hoff John S. Macdonald |
| |
| Affiliation: | (1) Cancer Research Center of Hawaii, USA;(2) Southwest Oncology Group Statistical Center, Seattle;(3) Columbus CCOP, USA;(4) Dayton CCOP, USA;(5) University of Michigan Medical Center, USA;(6) Virginia Mason CCOP, USA;(7) University of Texas Health Sciences Center, San Antonio;(8) University of Kentucky Medical Center, USA |
| |
| Abstract: | Summary In this multi-institutional phase II study, VM-26 or Teniposide was administered to forty-two patients with advanced colorectal cancer. Patients were initially treated at 60 mg/M2 daily for 5 days with dose adjustments depending on toxicity. One complete response and one partial response were observed lasting six and four months respectively. Leukopenia was severe in 40% of patients. No drug related deaths were seen. In this Southwest Oncology Group (SWOG) study, VM-26 appeared to have minimal benefit in advanced colorectal cancer.Address for offprints: Southwest Oncology Group (SWOG 8426), Operations Office, 5430 Fredericksburg Road, Suite #618, San Antonio, TX 78229, USA |
| |
| Keywords: | VM-26 chemotherapy advanced colorectal cancer |
| 本文献已被 SpringerLink 等数据库收录！ |
|
